Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.

Brain · 4 Nov 2026 · Journal Article · Open access

Hunt

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Open access

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis.
Brain · 4 Nov 2026 · Journal Article
AI summary · may contain errors
Low-dose IL-2 did not expand regulatory T cells in alemtuzumab-treated relapsing-remitting multiple sclerosis patients more than 6 months after therapy, despite prior in vitro and mouse selectivity.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42126089
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.

Related in JClub

Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis.

Browse JClub